One hundred and eight unselected patients with acute nonlymphocytic leukemia (ANLL) were treated with a combination of daunorubicin, cytosine arabinoside and 6-thioguanine (DAT). The complete remission rate was 54.6% and was achieved after an average of 2.3 courses of therapy. Among the initial variables, erythroleukemia morphology was the single most important prognostic factor, being associated with a poorer response rate (14.2%). Median remission duration was 48 weeks and median survival was 75 weeks; the estimated proportions of responders alive at 1 and 2 y from diagnosis were 71 and 35% respectively. Severe myelosuppression was the most common toxic effect observed during induction. DAT combination is an effective remission induction regimen for ANLL patients of all age groups. © 1979.

Daunorubicin, cytosine arabinoside and 6-thioguanine (DAT) combination chemotherapy for the treatment of acute non-lymphocytic leukemia / Sergio, Amadori; Giuseppe, Papa; Giovanna, Meloni; Leonardo, Pacilli; Mandelli, Franco. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - 3:3(1979), pp. 147-152. [10.1016/0145-2126(79)90012-2]

Daunorubicin, cytosine arabinoside and 6-thioguanine (DAT) combination chemotherapy for the treatment of acute non-lymphocytic leukemia

MANDELLI, Franco
1979

Abstract

One hundred and eight unselected patients with acute nonlymphocytic leukemia (ANLL) were treated with a combination of daunorubicin, cytosine arabinoside and 6-thioguanine (DAT). The complete remission rate was 54.6% and was achieved after an average of 2.3 courses of therapy. Among the initial variables, erythroleukemia morphology was the single most important prognostic factor, being associated with a poorer response rate (14.2%). Median remission duration was 48 weeks and median survival was 75 weeks; the estimated proportions of responders alive at 1 and 2 y from diagnosis were 71 and 35% respectively. Severe myelosuppression was the most common toxic effect observed during induction. DAT combination is an effective remission induction regimen for ANLL patients of all age groups. © 1979.
1979
acute nonlymphocytic leukemia; antileukemic drugs; combination chemotherapy
01 Pubblicazione su rivista::01a Articolo in rivista
Daunorubicin, cytosine arabinoside and 6-thioguanine (DAT) combination chemotherapy for the treatment of acute non-lymphocytic leukemia / Sergio, Amadori; Giuseppe, Papa; Giovanna, Meloni; Leonardo, Pacilli; Mandelli, Franco. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - 3:3(1979), pp. 147-152. [10.1016/0145-2126(79)90012-2]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/421503
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 7
  • ???jsp.display-item.citation.isi??? ND
social impact